0AAJ Stock Chart & Stats
CHF43.85
CHF0.10(0.23%)
At close: 4:00 PM EDT
CHF43.85
CHF0.10(0.23%)
Day’s Range― - ―
52-Week RangeCHF21.95 - CHF50.00
Previous CloseN/A
Volume19.92K
Average Volume (3M)14.85K
Market Cap
CHF1.45B
Enterprise ValueCHF1.63K
Total Cash (Recent Filing)CHF59.21M
Total Debt (Recent Filing)CHF139.52M
Price to Earnings (P/E)109.3
Beta1.19
Next Earnings
Mar 09, 2027EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding33,125,000
10 Day Avg. Volume4,273
30 Day Avg. Volume14,854
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF44.10Price Target Upside0.58% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.87
Revenue Forecast (FY)CHF496.39M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSteady top-line expansion indicates continued demand for peptide CDMO services and customer program activity. Sustained growth can improve plant utilization and provide a base for operating leverage as clinical projects mature into commercial supply.
Improving Operating Cash FlowPositive and improving operating cash flow demonstrates that core operations are generating funding despite reported losses. This supports ongoing development and manufacturing activities and reduces immediate reliance on external capital.
Moderate Debt Relative To EquityModerate debt relative to the equity base provides financial flexibility for a specialized manufacturing business. Although leverage has risen, the current capital structure offers more resilience than a highly debt-funded expansion model.
Bears Say
Persistent Losses And Margin PressurePersistent net losses and sharply compressed margins show that revenue growth has not yet translated into durable profitability. This limits internally funded expansion and leaves results sensitive to utilization, mix, and execution.
Volatile Free Cash FlowNegative and volatile free cash flow indicates that investment requirements or working-capital needs can absorb operating cash generation. Continued volatility may constrain capacity expansion and increase dependence on balance-sheet resources.
Rising Leverage And Declining EquityHigher debt alongside declining equity weakens the company’s financial trajectory, even though absolute leverage remains moderate. If losses persist, reduced equity could limit flexibility and increase sensitivity to funding and execution risks.
PolyPeptide Group AG News
0AAJ FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest share price was CHF21.95 and its highest was CHF50.00 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.45B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Mar 09, 2027 which is in 199 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Aug 13, 2026. The company reported CHF0.252 earnings per share for the quarter, beating the consensus estimate of CHF0.065 by CHF0.187.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.57.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of CHF0.252 in its last earnings report, beating expectations of CHF0.065. Following the earnings report the stock price went up 0.059%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in GB:0AAJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
0AAJ Stock 12 Month Forecast
Average Price Target
CHF44.10
▲(0.58% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Joincare Pharmaceutical Group Industry Co., Ltd. Sponsored GDR Class A RegS
―